<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01506271</url>
  </required_header>
  <id_info>
    <org_study_id>7655-004</org_study_id>
    <secondary_id>2011-005686-20</secondary_id>
    <secondary_id>MK-7655-004</secondary_id>
    <nct_id>NCT01506271</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)</brief_title>
  <official_title>A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients With Complicated Intra-Abdominal Infection [cIAI]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125
      mg or 250 mg doses of relebactam (MK-7655) to imipenem/cilastatin in adults 18 years or older
      with Complicated Intra-Abdominal Infection (cIAI). The primary hypothesis is that the
      relebactam + imipenem/cilastatin treatment regimen is non-inferior to treatment with
      imipenem/cilastatin alone with respect to the percentage of participants with a favorable
      clinical response at completion of intravenous (IV) study therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2012</start_date>
  <completion_date type="Actual">August 12, 2014</completion_date>
  <primary_completion_date type="Actual">August 12, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy</measure>
    <time_frame>4 to 14 days post initiation of intravenous (IV) study therapy (up to postrandomization Day 14)</time_frame>
    <description>A favorable clinical response was assessed by the clinical investigator as a cure, and was defined as a situation where all or most pre-therapy signs and symptoms of the index infection had resolved, or returned to pre-infection status, and no additional antibiotic therapy was required.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Elevated Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Laboratory Values That Are Greater Than or Equal to 5X the Upper Limit of Normal (ULN)</measure>
    <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
    <description>Pre-specified events of interest were confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 5 X ULN as a result of within-protocol-specific testing or unscheduled testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Elevated AST or ALT Laboratory Values &gt;= 3X the ULN, Total Bilirubin &gt;= 2X the ULN, and Alkaline Phosphatase Values &lt; 2X the ULN</measure>
    <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
    <description>Pre-specified events of interest were a confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 3X ULN, as well as elevated total bilirubin greater than or equal to 2X the ULN, and alkaline phosphatase values that are less than 2X the ULN, as a result of within-protocol-specific testing or unscheduled testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Adverse Event (AE)</measure>
    <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
    <description>A serious adverse event (SAE) is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Drug-related AE</measure>
    <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is a AE determined by the investigator to be possibly, probably or definitely related to drug treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Any Drug-related SAE</measure>
    <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
    <description>A SAE is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death. A drug-related SAE is a SAE determined by the investigator to be possibly, probably or definitely related to drug treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued IV Study Therapy Due to an AE</measure>
    <time_frame>Up to 14 days post initiation of IV study therapy (up to 14 days)</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AEs assessed by the investigator that caused discontinuation of participant treatment are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued IV Study Therapy Due to a Drug-related AE</measure>
    <time_frame>Up to 14 days post initiation of IV study therapy (up to 14 days)</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is an AE determined by the investigator to be possibly, probably or definitely related to drug treatment. Drug-related AEs assessed by the investigator that caused discontinuation of participant treatment are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Specific AEs With Incidence of &gt;= 4 Participants in One Treatment Group</measure>
    <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
    <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AE preferred terms, with incidence greater than or equal to 4 in one treatment group are presented. AEs preferred terms which did not achieve this threshold are not reported. AE preferred terms are based on MedDRA version 17.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Predefined Limit of Change (PDLC) With Incidence of &gt;= 4 Participants in One Treatment Group</measure>
    <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
    <description>Predefined limit of change (PDLC) are presented based on values from the following laboratory tests on serum: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Bil), and alkaline phosphatase (AP). Results are presented for PDLC from tests with reported incidence greater than or equal to 4 participants in one treatment group. Laboratory tests which did not achieve the PDLC threshold are not reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With System Organ Class (SOC) With AEs With Incidence of &gt;= 4 Participants in One Treatment Group</measure>
    <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
    <description>A system organ class (SOC) is the highest level of terminology used to describe disorders of the human body, and distinguishes by either anatomical or physiological systems, disease origin or purpose. SOCs with AE incidence greater than or equal to 4 in one treatment group are presented. SOCs with AE incidence which did not achieve this threshold are not reported. SOCs are based on MedDRA version 17.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy in Participants Who Have Imipenem-resistant, Gram-negative cIAI Infections.</measure>
    <time_frame>4 to 14 days post initiation of IV study therapy (up to postrandomization day 14).</time_frame>
    <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Early Follow-up</measure>
    <time_frame>Up to 9 days following completion of all study therapy (up to Day 23)</time_frame>
    <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy</measure>
    <time_frame>Up to 14 days post initiation of IV study therapy (up to postrandomization day 14)</time_frame>
    <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at Early Follow-up</measure>
    <time_frame>Up to 9 days following completion of all study therapy (up to Day 23)</time_frame>
    <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Late Follow-up</measure>
    <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
    <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at Late Follow-up</measure>
    <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
    <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">351</enrollment>
  <condition>Intra-abdominal Infections</condition>
  <arm_group>
    <arm_group_label>Relebactam 250 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relebactam 125 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo to relebactam with imipenem/cilastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relebactam 250 mg</intervention_name>
    <description>Relebactam 250 mg IV every 6 hours for a minimum of 96 hours</description>
    <arm_group_label>Relebactam 250 mg with imipenem/cilastatin</arm_group_label>
    <other_name>MK-7655</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Relebactam 125 mg</intervention_name>
    <description>Relebactam 125 mg IV every 6 hours for a minimum of 96 hours</description>
    <arm_group_label>Relebactam 125 mg with imipenem/cilastatin</arm_group_label>
    <other_name>MK-7655</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem/cilastatin</intervention_name>
    <description>A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.</description>
    <arm_group_label>Placebo to relebactam with imipenem/cilastatin</arm_group_label>
    <arm_group_label>Relebactam 125 mg with imipenem/cilastatin</arm_group_label>
    <arm_group_label>Relebactam 250 mg with imipenem/cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo to relebactam</intervention_name>
    <description>Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.</description>
    <arm_group_label>Placebo to relebactam with imipenem/cilastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically suspected and/or bacteriologically documented cIAI requiring
             hospitalization and treatment with IV antibiotic therapy.

          -  Enrolled intraoperatively or postoperatively on the basis of operative findings OR
             enrolled preoperatively on the basis of compelling preoperative clinical findings.

        Exclusion Criteria:

          -  Infection which should be managed by Staged Abdominal Repair (STAR) or open abdomen
             technique.

          -  Acute Physiology and Chronic Health Evaluation II (APACHE II) score greater than 30.

          -  Any amount of effective antibiotic therapy after obtaining the culture for admission
             to this study and prior to the administration of the first dose of IV study therapy.

          -  An infection which has been treated with &gt;24 hours of systemic antibiotic therapy
             known to be effective against the presumed or documented etiologic pathogen(s) within
             the 72-hour period immediately prior to consideration for entry into the study.

          -  History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious
             reaction to carbapenem antibiotics, any cephalosporins, penicillins, or other β-lactam
             agents.

          -  History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious
             reaction to other β-lactamase inhibitors (e.g., tazobactam, sulbactam, clavulanic
             acid).

          -  History of a seizure disorder (requiring ongoing treatment with anticonvulsive therapy
             or prior treatment with anti-convulsive therapy in the last 3 years).

          -  Currently being treated with valproic acid or has used valproic acid in the 2 weeks
             prior to screening.

          -  Rapidly progressive or terminal illness (unlikely to survive the approximately 6- to
             8-week study period).

          -  Pregnant or expecting to conceive, breastfeeding, or plans to breast feed within 1
             month of completion of the study.

          -  Participant in whom a response to IV study therapy within the timeframe of treatment
             specified in this protocol is considered unlikely.

          -  Concurrent infection that would interfere with evaluation of response to the study
             antibiotics.

          -  Need for concomitant systemic antimicrobial agents in addition to those designated in
             the various study treatment groups.

          -  cIAI due to a confirmed fungal pathogen.

          -  Currently receiving immunosuppressive therapy, including use of high-dose
             corticosteroids.

          -  Prior recipient of a renal transplantation.

          -  Estimated or actual creatinine clearance of &lt;50 mL/minute.

          -  History of any other illness that, in the opinion of the investigator, might confound
             the results of the study or pose additional risk in administering the study drug to
             the patient.

          -  Laboratory abnormalities as specified in protocol.

          -  Currently participating in, or has participated in any other clinical study involving
             the administration of investigational or experimental medication (not licensed by
             regulatory agencies) at the time of presentation or during the previous 30 days prior
             to screening or is anticipated to participate in such a clinical study during the
             course of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A. Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43. doi: 10.1128/AAC.00633-16. Print 2016 Oct.</citation>
    <PMID>27503659</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2012</study_first_posted>
  <results_first_submitted>April 26, 2019</results_first_submitted>
  <results_first_submitted_qc>June 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2019</results_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Complicated Intra-abdominal Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>MK-7655</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults 18 years or older with complicated intra-abdominal infection (cIAI) requiring treatment with intravenous (IV) antibiotic therapy were enrolled in this study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
          <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
        <group group_id="P2">
          <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
          <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
        <group group_id="P3">
          <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
          <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient supply of study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
          <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
        <group group_id="B2">
          <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
          <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
        <group group_id="B3">
          <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
          <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="117"/>
            <count group_id="B4" value="351"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" spread="18.9"/>
                    <measurement group_id="B2" value="49.8" spread="17.4"/>
                    <measurement group_id="B3" value="49.1" spread="17.8"/>
                    <measurement group_id="B4" value="49.1" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy</title>
        <description>A favorable clinical response was assessed by the clinical investigator as a cure, and was defined as a situation where all or most pre-therapy signs and symptoms of the index infection had resolved, or returned to pre-infection status, and no additional antibiotic therapy was required.</description>
        <time_frame>4 to 14 days post initiation of intravenous (IV) study therapy (up to postrandomization Day 14)</time_frame>
        <population>Those who had cIAI; a culture from the infection that grew one Gram negative pathogen; no protocol deviations; received ≥ 96 hours of IV therapy. Two participants treated with relebactam 250 mg, one with relebactam 125 mg, and two with placebo, all with indeterminate or missing responses, were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy</title>
          <description>A favorable clinical response was assessed by the clinical investigator as a cure, and was defined as a situation where all or most pre-therapy signs and symptoms of the index infection had resolved, or returned to pre-infection status, and no additional antibiotic therapy was required.</description>
          <population>Those who had cIAI; a culture from the infection that grew one Gram negative pathogen; no protocol deviations; received ≥ 96 hours of IV therapy. Two participants treated with relebactam 250 mg, one with relebactam 125 mg, and two with placebo, all with indeterminate or missing responses, were excluded from the analysis.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="89.6" upper_limit="99.2"/>
                    <measurement group_id="O2" value="98.8" lower_limit="93.7" upper_limit="100"/>
                    <measurement group_id="O3" value="95.2" lower_limit="88.1" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>MK-7655 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority test based on unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority test based on unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Elevated Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Laboratory Values That Are Greater Than or Equal to 5X the Upper Limit of Normal (ULN)</title>
        <description>Pre-specified events of interest were confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 5 X ULN as a result of within-protocol-specific testing or unscheduled testing.</description>
        <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Elevated Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) Laboratory Values That Are Greater Than or Equal to 5X the Upper Limit of Normal (ULN)</title>
          <description>Pre-specified events of interest were confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 5 X ULN as a result of within-protocol-specific testing or unscheduled testing.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for a non-zero difference.</non_inferiority_desc>
            <p_value>0.979</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for a non-zero difference.</non_inferiority_desc>
            <p_value>0.153</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Elevated AST or ALT Laboratory Values &gt;= 3X the ULN, Total Bilirubin &gt;= 2X the ULN, and Alkaline Phosphatase Values &lt; 2X the ULN</title>
        <description>Pre-specified events of interest were a confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 3X ULN, as well as elevated total bilirubin greater than or equal to 2X the ULN, and alkaline phosphatase values that are less than 2X the ULN, as a result of within-protocol-specific testing or unscheduled testing.</description>
        <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated AST or ALT Laboratory Values &gt;= 3X the ULN, Total Bilirubin &gt;= 2X the ULN, and Alkaline Phosphatase Values &lt; 2X the ULN</title>
          <description>Pre-specified events of interest were a confirmed (i.e., verified by repeat testing) elevated AST or ALT laboratory value that is greater than or equal to 3X ULN, as well as elevated total bilirubin greater than or equal to 2X the ULN, and alkaline phosphatase values that are less than 2X the ULN, as a result of within-protocol-specific testing or unscheduled testing.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for a non-zero difference.</non_inferiority_desc>
            <p_value>0.324</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Test for a non-zero difference</non_inferiority_desc>
            <p_value>&gt; 0.999</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Adverse Event (AE)</title>
        <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE.</description>
        <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Event (AE)</title>
          <description>An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="41.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>20.1</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>18.8</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Serious Adverse Event (SAE)</title>
        <description>A serious adverse event (SAE) is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death.</description>
        <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Serious Adverse Event (SAE)</title>
          <description>A serious adverse event (SAE) is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="9.5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Drug-related AE</title>
        <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is a AE determined by the investigator to be possibly, probably or definitely related to drug treatment.</description>
        <time_frame>Up to 14 days following completion of all study therapy (up to Day 28)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Drug-related AE</title>
          <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is a AE determined by the investigator to be possibly, probably or definitely related to drug treatment.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>12.7</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Drug-related SAE</title>
        <description>A SAE is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death. A drug-related SAE is a SAE determined by the investigator to be possibly, probably or definitely related to drug treatment.</description>
        <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Drug-related SAE</title>
          <description>A SAE is any AE occurring at any dose that is life threatening; results in a persistent or significant disability/incapacity; prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; or results in death. A drug-related SAE is a SAE determined by the investigator to be possibly, probably or definitely related to drug treatment.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued IV Study Therapy Due to an AE</title>
        <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AEs assessed by the investigator that caused discontinuation of participant treatment are presented.</description>
        <time_frame>Up to 14 days post initiation of IV study therapy (up to 14 days)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued IV Study Therapy Due to an AE</title>
          <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AEs assessed by the investigator that caused discontinuation of participant treatment are presented.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Discontinued IV Study Therapy Due to a Drug-related AE</title>
        <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is an AE determined by the investigator to be possibly, probably or definitely related to drug treatment. Drug-related AEs assessed by the investigator that caused discontinuation of participant treatment are presented.</description>
        <time_frame>Up to 14 days post initiation of IV study therapy (up to 14 days)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued IV Study Therapy Due to a Drug-related AE</title>
          <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. A drug-related AE is an AE determined by the investigator to be possibly, probably or definitely related to drug treatment. Drug-related AEs assessed by the investigator that caused discontinuation of participant treatment are presented.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Specific AEs With Incidence of &gt;= 4 Participants in One Treatment Group</title>
        <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AE preferred terms, with incidence greater than or equal to 4 in one treatment group are presented. AEs preferred terms which did not achieve this threshold are not reported. AE preferred terms are based on MedDRA version 17.0.</description>
        <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Specific AEs With Incidence of &gt;= 4 Participants in One Treatment Group</title>
          <description>An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an AE. AE preferred terms, with incidence greater than or equal to 4 in one treatment group are presented. AEs preferred terms which did not achieve this threshold are not reported. AE preferred terms are based on MedDRA version 17.0.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="7.8"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="7.8"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-operative wound infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Diarrhoea</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Diarrhoea</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Nausea</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Nausea</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Vomiting</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Vomiting</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Postoperative Infection</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.6</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Postoperative Infection</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Seroma</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Seroma</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>9.7</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - ALT increased</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - ALT increased</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>6.7</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - AST increased</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - AST increased</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Lipase increased</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Lipase increased</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Hypertension</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Hypertension</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy in Participants Who Have Imipenem-resistant, Gram-negative cIAI Infections.</title>
        <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
        <time_frame>4 to 14 days post initiation of IV study therapy (up to postrandomization day 14).</time_frame>
        <population>Met the protocol definition of cIAI; had a culture from the site of infection, that grew Gram-negative pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; received ≥ 96 hours of IV study therapy; and had imipenem-resistant, gram negative cIAI infections.</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Favorable Clinical Response at Completion of IV Study Therapy in Participants Who Have Imipenem-resistant, Gram-negative cIAI Infections.</title>
          <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
          <population>Met the protocol definition of cIAI; had a culture from the site of infection, that grew Gram-negative pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; received ≥ 96 hours of IV study therapy; and had imipenem-resistant, gram negative cIAI infections.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="76.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="66.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="71.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.999</p_value>
            <method>Fisher Exact</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt; 0.999</p_value>
            <method>Fisher Exact</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Favorable Clinical Response at Early Follow-up</title>
        <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
        <time_frame>Up to 9 days following completion of all study therapy (up to Day 23)</time_frame>
        <population>Met the protocol definition of cIAI; had a culture from the site of infection, that grew Gram-negative pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; received ≥ 96 hours of IV study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Favorable Clinical Response at Early Follow-up</title>
          <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
          <population>Met the protocol definition of cIAI; had a culture from the site of infection, that grew Gram-negative pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; received ≥ 96 hours of IV study therapy.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="87.5" upper_limit="98.6"/>
                    <measurement group_id="O2" value="94.2" lower_limit="87.0" upper_limit="98.1"/>
                    <measurement group_id="O3" value="96.3" lower_limit="89.6" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>6.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy</title>
        <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
        <time_frame>Up to 14 days post initiation of IV study therapy (up to postrandomization day 14)</time_frame>
        <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Favorable Microbiological Response at Completion of IV Study Therapy</title>
          <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
          <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="86"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="91.6" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O3" value="97.6" lower_limit="91.7" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Two participants with indeterminate or missing response were excluded from the analysis.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Two participants with indeterminate or missing response were excluded from the analysis.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Favorable Microbiological Response at Early Follow-up</title>
        <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
        <time_frame>Up to 9 days following completion of all study therapy (up to Day 23)</time_frame>
        <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Favorable Microbiological Response at Early Follow-up</title>
          <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
          <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="91.0" upper_limit="99.7"/>
                    <measurement group_id="O2" value="97.6" lower_limit="91.5" upper_limit="99.7"/>
                    <measurement group_id="O3" value="97.5" lower_limit="91.3" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Eight participants with indeterminate or missing response were excluded from the analysis.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.7</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Eight participants with indeterminate or missing response were excluded from the analysis.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.3</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Favorable Clinical Response at Late Follow-up</title>
        <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
        <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
        <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Favorable Clinical Response at Late Follow-up</title>
          <description>A favorable clinical response is assessed by the clinical investigator as a cure, and is defined as a situation where all or most pre-therapy signs and symptoms of the index infection have resolved, or returned to pre-infection status, and no additional antibiotic therapy is required.</description>
          <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" lower_limit="85.8" upper_limit="97.9"/>
                    <measurement group_id="O2" value="95.3" lower_limit="88.4" upper_limit="98.7"/>
                    <measurement group_id="O3" value="94.9" lower_limit="87.5" upper_limit="98.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority test based on Unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <p_value>0.002</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.6</ci_lower_limit>
            <ci_upper_limit>6.9</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>8.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Favorable Microbiological Response at Late Follow-up</title>
        <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
        <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
        <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Favorable Microbiological Response at Late Follow-up</title>
          <description>A favorable microbiological response is assessed by the clinical investigator, and is defined as the eradication or presumptive eradication of all bacterial pathogens identified at baseline.</description>
          <population>Met the protocol definition of cIAI; had a pre-study/post operative culture from the site of infection grew at least one Gram-negative enteric and/or anaerobic pathogen; had no significant deviations from the protocol that could impact the efficacy assessment; and received ≥ 96 hours of IV study therapy.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2" lower_limit="89.2" upper_limit="99.2"/>
                    <measurement group_id="O2" value="97.5" lower_limit="91.4" upper_limit="99.7"/>
                    <measurement group_id="O3" value="96.2" lower_limit="89.2" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Eight participants with indeterminate or missing response were excluded from the analysis.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Eight participants with indeterminate or missing response were excluded from the analysis.</non_inferiority_desc>
            <p_value>&lt; 0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Percentage Difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Predefined Limit of Change (PDLC) With Incidence of &gt;= 4 Participants in One Treatment Group</title>
        <description>Predefined limit of change (PDLC) are presented based on values from the following laboratory tests on serum: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Bil), and alkaline phosphatase (AP). Results are presented for PDLC from tests with reported incidence greater than or equal to 4 participants in one treatment group. Laboratory tests which did not achieve the PDLC threshold are not reported.</description>
        <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Predefined Limit of Change (PDLC) With Incidence of &gt;= 4 Participants in One Treatment Group</title>
          <description>Predefined limit of change (PDLC) are presented based on values from the following laboratory tests on serum: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (Bil), and alkaline phosphatase (AP). Results are presented for PDLC from tests with reported incidence greater than or equal to 4 participants in one treatment group. Laboratory tests which did not achieve the PDLC threshold are not reported.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT &gt;2.5-5.0 X Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT &gt;5.0 X Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5"/>
                    <measurement group_id="O2" value="6.1"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST &gt;2.5-5.0 X Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5"/>
                    <measurement group_id="O2" value="14.0"/>
                    <measurement group_id="O3" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AP &gt;2.5-5.0 X Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With System Organ Class (SOC) With AEs With Incidence of &gt;= 4 Participants in One Treatment Group</title>
        <description>A system organ class (SOC) is the highest level of terminology used to describe disorders of the human body, and distinguishes by either anatomical or physiological systems, disease origin or purpose. SOCs with AE incidence greater than or equal to 4 in one treatment group are presented. SOCs with AE incidence which did not achieve this threshold are not reported. SOCs are based on MedDRA version 17.0.</description>
        <time_frame>Up to 42 days following completion of all study therapy (up to Day 56)</time_frame>
        <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O2">
            <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
            <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
            <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With System Organ Class (SOC) With AEs With Incidence of &gt;= 4 Participants in One Treatment Group</title>
          <description>A system organ class (SOC) is the highest level of terminology used to describe disorders of the human body, and distinguishes by either anatomical or physiological systems, disease origin or purpose. SOCs with AE incidence greater than or equal to 4 in one treatment group are presented. SOCs with AE incidence which did not achieve this threshold are not reported. SOCs are based on MedDRA version 17.0.</description>
          <population>All randomized participants who received at least one dose of IV study therapy, based on the therapy they actually received</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="116"/>
                <count group_id="O3" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and lymphatic system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="17.2"/>
                    <measurement group_id="O3" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General disorders admin. site conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="5.2"/>
                    <measurement group_id="O3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="7.8"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury, poisoning, procedural complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous system disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and urinary disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory, thoracic, mediastinal disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin, subcutaneous tissue disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="6.0"/>
                    <measurement group_id="O3" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Blood, lymphatic</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Blood, lymphatic</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Cardiac disorder</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Cardiac disorder</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.5</ci_lower_limit>
            <ci_upper_limit>6.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - GI disorders</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>15.3</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - GI disorders</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>13.6</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Gen. dis &amp; admin.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>11.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Gen. dis &amp; admin.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Infect. &amp; Infest.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>4.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>12.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Infect. &amp; Infest.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>8.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Injury, poison.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 1250mg - Placebo: Percentage Difference - Injury, poison.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Investigations</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Investigations</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Nervous System</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Nervous System</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Psychiatric disorders</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>5.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Psychiatric disorders</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Renal &amp; Urinary</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Renal &amp; Urinary</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.2</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Resp. &amp; chest</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.7</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Resp. &amp; chest</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.4</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Skin &amp; subcutan.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Skin &amp; subcutan.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 250 mg - Placebo: Percentage Difference - Vascular disorders</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relebactam 125 mg - Placebo: Percentage Difference - Vascular disorders</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Unconditional asymptotic Miettinen and Nurminen method without stratification</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
            <estimate_desc>Relebactam minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During study therapy and the protocol-specified follow-up period following end of study therapy (up to 28 days for non-serious AEs and up to 56 days for serious AEs)</time_frame>
      <desc>Population analyzed is all randomized participants who received at least one dose of IV study therapy. Participants with All-Cause Mortality were determined by the investigator to include some participants discontinued due to an adverse event, and progressive disease.</desc>
      <group_list>
        <group group_id="E1">
          <title>Relebactam 250 mg With Imipenem/Cilastatin</title>
          <description>Participants received relebactam 250 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
        <group group_id="E2">
          <title>Relebactam 125 mg With Imipenem/Cilastatin</title>
          <description>Participants received relebactam 125 mg IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
        <group group_id="E3">
          <title>Placebo to Relebactam With Imipenem/Cilastatin</title>
          <description>Participants received matching placebo to relebactam (normal saline 0.9%) IV with imipenem/cilastatin 500 mg IV every 6 hours for a minimum of 96 hours</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Mucinous adenocarcinoma of appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="116"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="117"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="114"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="114"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

